Details for New Drug Application (NDA): 006328
✉ Email this page to a colleague
NDA 006328 describes ISUPREL, which is a drug marketed by Sanofi Aventis Us and Bausch and is included in four NDAs. Additional details are available on the ISUPREL profile page.
The generic ingredient in ISUPREL is isoproterenol hydrochloride. There are seventeen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the isoproterenol hydrochloride profile page.
The generic ingredient in ISUPREL is isoproterenol hydrochloride. There are seventeen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the isoproterenol hydrochloride profile page.
Summary for 006328
| Tradename: | ISUPREL |
| Applicant: | Sanofi Aventis Us |
| Ingredient: | isoproterenol hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;RECTAL, SUBLINGUAL | Strength | 10MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;RECTAL, SUBLINGUAL | Strength | 15MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
